The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease
Abstract
Background— The clustering of impaired glucose metabolism, elevated triglycerides, low HDL cholesterol, and abdominal obesity is known as the metabolic syndrome. Individuals with this syndrome suffer an excess of cardiovascular disease (CVD) for reasons that are unclear. Methods and Results— We randomly sampled 1276 adults of South Asian, Chinese, European, and Native Indian ancestry from 4 communities in Canada. Participants provided fasting blood samples for glucose, lipids, and fibrinolytic measurements; had an oral glucose tolerance test; and underwent a B-mode carotid ultrasound examination. CVD was determined by history and ECG. The prevalence of the metabolic syndrome was 25.8% (95% CI, 23.5 to 28.2) and varied substantially by ethnic group: 41.6% among Native Indians, 25.9% among South Asians, and 22.0% among Europeans, compared with 11.0% among the Chinese (overall, P =0.0001). People with the metabolic syndrome had more atherosclerosis (maximum intimal medial thickness, 0.78±0.18 versus 0.74±0.18 mm; P =0.0005), CVD (17.2% versus 7.0%; P =0.0001), and elevated plasminogen activator inhibitor-1 (24.2 versus 14.6 U/mL; P =0.001) compared with levels among people without the metabolic syndrome. For the same amount of atherosclerosis, people with the metabolic syndrome had a greater prevalence of CVD, even among nondiabetic individuals. This difference in CVD prevalence among the groups was attenuated after adjustment for plasminogen activator inhibitor-1 levels, suggesting that fibrinolytic dysfunction mediates the increased risk of CVD in individuals with the metabolic syndrome. Conclusion— CVD among people with the metabolic syndrome is explained by their excess of atherosclerosis and impaired fibrinolysis. Interventions to prevent atherosclerosis progression and improve fibrinolytic function require evaluation in this high-risk group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Larsson, B., Svärdsudd, K., Welin, L., Wilhelmsen, L., Björntorp, P., & Tibblin, G. (1984) · BMJ · doi:10.1136/bmj.288.6428.1401 · Cited by 1,934
Thompson, S. G., Kienast, J., Pyke, S. D. M., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,821
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Hamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
Anand, S. S., Yusuf, S., Vuksan, V., Devanesen, S., Teo, K. K., Montague, P. A., Kelemen, L., Yi, C., Lonn, E., Gerstein, H., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02502-2 · Cited by 1,066
Self-citation
Cited by
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H.-M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 632
Myers, J., Lee, M., & Kiratli, J. (2007) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e31802f0247 · Cited by 585
Calorie restriction in humans: An update
Most, J., Tosti, V., Redman, L. M., & Fontana, L. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.08.005 · Cited by 530
Obesity-related non-communicable diseases: South Asians vs White Caucasians
Misra, A., & Khurana, L. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.135 · Cited by 469
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390
Metadata
- Authors
- Anand, S. S., Yi, Q., Gerstein, H., Lonn, E., Jacobs, R., Vuksan, V., Teo, K., Davis, B., Montague, P., & Yusuf, S.
- Venue
- Circulation
- Published
- 2003-07-29
- Volume
- 108
- Issue
- 4
- Pages
- 420-425
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2157914295
- Cited by
- 285
- References
- 31
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. https://app.cochat.ai/papers/10.1161/01.cir.0000080884.27358.49
- The paper
- Anand, S. S., Yi, Q., Gerstein, H., Lonn, E., Jacobs, R., Vuksan, V., Teo, K., Davis, B., Montague, P., & Yusuf, S. (2003). Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. Circulation. https://doi.org/10.1161/01.cir.0000080884.27358.49
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.